Kymera’s partnerships with Sanofi and Gilead drive value
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Stifel Defending Kymera Therapeutics (KYMR): 'We see any weakness from today's news as a buying opportunity'
June 27, 2025 12:19 PM EDTStifel analyst Alex Thompson reiterated a Buy rating and $68.00 price target on Kymera Therapeutics (NASDAQ: KYMR).
The analyst comments "We are reiterating our Buy Rating on KYMR following a slate of updates including the decision by partner Sanofi to discontinue development of... More
